What are the new drugs for Sjögren's Syndrome?

Overview of Sjögren's Syndrome 
Sjögren's Syndrome is a chronic, systemic autoimmune disorder characterized primarily by lymphocytic infiltration of the exocrine glands—most notably the lacrimal and salivary glands—which results in the hallmark symptoms of dry eyes (keratoconjunctivitis sicca) and dry mouth (xerostomia). Patients frequently report a persistent sensation of dryness accompanied by irritation, burning, and a foreign body sensation in the eyes, along with difficulty swallowing, dental decay, and oral discomfort due to diminished saliva production. In addition to these glandular symptoms, many patients experience extraglandular manifestations such as arthralgia, fatigue, and, in some cases, involvement of the kidneys, lungs, and nervous system. The multifaceted clinical presentation renders diagnosis challenging and often leads to significant diagnostic delays, further exacerbating the patient’s quality of life. 

Current Treatment Landscape 
Historically, the management of Sjögren's Syndrome has been primarily symptomatic. Patients are commonly treated with topical interventions such as artificial tears and saliva substitutes to alleviate dryness. Systemic therapies—including hydroxychloroquine, corticosteroids, and other immunosuppressants—have been used to manage extraglandular manifestations; however, clinical responses have been variable and often modest. There is currently an unmet medical need for disease-modifying drugs that address the underlying immunopathogenic mechanisms rather than just providing symptomatic relief. Given the heterogeneity in symptoms and disease activity, conventional therapeutic options have not been uniformly successful, which has spurred significant research into the development of novel therapeutic agents aimed at modifying the disease course.

Recent Developments in Drug Treatments

Newly Approved Drugs 
At present, no drug has been specifically approved by major regulatory agencies solely for the disease-modifying treatment of Sjögren's Syndrome. The current newly developed agents are predominantly still in clinical trials, reflecting the evolving understanding of the immunopathology behind the syndrome. Although some agents (e.g., those originally approved for other autoimmune disorders) are being repurposed for Sjögren's, there remains a trend toward developing treatments that specifically address key molecular pathways implicated in Sjögren's. For example, while drugs such as rituximab (an anti-CD20 monoclonal antibody) have been widely used off‐label, their clinical benefit remains inconsistent, prompting the need for novel, targeted therapies.

Drugs in Clinical Trials 
The most promising advancements in drug development for Sjögren's Syndrome have been observed among agents targeting co‐stimulatory signals and Fc receptor pathways. A notable candidate is dazodalibep, a fully human CD40 ligand antagonist. In multiple Phase 2 clinical trials, dazodalibep has demonstrated statistically significant improvements in the EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI), with patients showing a reduction of 6.3 points compared to the 4.1‐point reduction observed with placebo. These promising results suggest that blocking the CD40–CD40L pathway can attenuate pathogenic T cell–B cell interactions, effectively modulating disease activity. 

Another investigational agent garnering attention is nipocalimab, an FcRn (neonatal Fc receptor) antagonist that works by accelerating the clearance of circulating immunoglobulins, including pathogenic autoantibodies. Preliminary data presented from early-phase trials in Sjögren’s Syndrome indicate that nipocalimab may induce a rapid decrease in total IgG and autoantibodies such as anti-Ro60 and anti-La, thereby providing early proof of concept for FcRn blockade in this condition. 

In addition to these biologics, there is also emerging evidence regarding the role of traditional medicine derivatives. Total glucosides of paeony (TGP), extracted from the white peony root, have shown immunomodulatory properties and have been the subject of systematic reviews for their efficacy in primary Sjögren's Syndrome. Studies have demonstrated that TGP combined with an immunosuppressant may improve salivary flow, reduce inflammatory markers, and has an acceptable safety profile. 

Other agents under investigation include certain B-cell targeting strategies such as novel anti-CD20 products and BAFF (B-cell activating factor) inhibitors; however, the most robust current data have been generated with agents like dazodalibep and nipocalimab. The clinical focus is increasingly shifting towards agents that not only provide symptomatic relief but directly target the pathogenic mechanisms involved in glandular dysfunction.

Mechanisms of Action

How New Drugs Work 
The new drugs for Sjögren's Syndrome are being designed to intervene at specific points in the immune cascade that drive the disease pathology. Dazodalibep, for instance, inhibits the CD40 ligand, a critical mediator expressed on activated T cells that interacts with CD40 receptors on B cells and antigen-presenting cells. By blocking this interaction, dazodalibep disrupts the subsequent activation of B cells and the formation of autoantibodies, a process central to the pathogenesis of Sjögren's Syndrome. This targeted approach aims to reduce the inflammatory signals that lead to glandular damage.

Nipocalimab operates by antagonizing the neonatal Fc receptor (FcRn), which is responsible for protecting IgG antibodies from lysosomal degradation. By inhibiting FcRn, nipocalimab accelerates the clearance of circulating antibodies, including detrimental autoantibodies implicated in Sjögren's Syndrome. The reduction in autoantibody levels may help in restoring normal glandular function and alleviate systemic inflammation.

Total glucosides of paeony, derived from traditional Chinese medicine, exert their effects through multiple immunomodulatory pathways. They have been shown to downregulate inflammatory cytokines and modulate the immune response, thereby reducing the degree of glandular inflammation and improving saliva production. These agents offer a multimodal mechanism of action that may complement more targeted biologic therapies.

Comparison with Existing Treatments 
In contrast to conventional treatments, which have been largely symptomatic and non-specific (e.g., artificial tears, saliva substitutes, corticosteroids), these new drug candidates work at the molecular level to modify the underlying autoimmune process. Rituximab, an older anti-CD20 therapy, while effective in depleting B cells, has produced mixed clinical results in Sjögren's Syndrome, and its benefits are often transient with significant variability among patients. Conversely, the new agents like dazodalibep and nipocalimab are designed with a clear understanding of disease pathophysiology in mind, aiming to provide a more sustained and targeted immunomodulation. Furthermore, TGP offers an additional approach by harnessing natural compounds with multi-target effects, potentially balancing efficacy with fewer side effects compared to systemic immunosuppressants. These novel mechanisms represent a paradigm shift from protective–symptomatic care to active disease modification.

Efficacy and Safety

Clinical Trial Results 
The efficacy of dazodalibep in Sjögren's Syndrome has been one of the most encouraging findings in recent clinical investigations. In a Phase 2 randomized placebo-controlled trial, patients receiving dazodalibep experienced a statistically significant reduction in their ESSDAI scores—approximately a 6.3‐point reduction versus a 4.1‐point change in the placebo group. Such improvements were accompanied by positive trends in secondary endpoints, including symptom and quality-of-life measures such as the EULAR Sjögren's Syndrome Patient-Reported Index (ESSPRI) and fatigue scores. 

Early data from nipocalimab trials also support its potential efficacy, with initial reports showing a rapid decrease in immunoglobulin levels and pathogenic autoantibodies, which are believed to correlate with clinical improvements. Although these results are preliminary, they provide a solid basis for further exploration in larger, more definitive studies. 

In the realm of traditional medicine, meta-analyses and systematic reviews of TGP have demonstrated significant improvement in objective measures such as salivary flow and Schirmer’s test results, along with reductions in biochemical inflammatory markers like ESR, CRP, IgM, and IgG. These findings support the potential of TGP as an effective adjunct treatment when used in combination with standard immunosuppressants.

Side Effects and Safety Profiles 
Safety profiles of these emerging drugs are of paramount importance given the chronic nature of Sjögren's Syndrome and the need for long-term management. Dazodalibep has been reported to be well tolerated overall; the most frequent adverse events in the Phase 2 trials included common events such as COVID-19 infections, diarrhea, dizziness, and ligament sprains, which were comparable in frequency to those in the placebo group. Importantly, there were no serious drug-related adverse events that would preclude its further development.

Nipocalimab, though still in the early stages of evaluation, has shown a tolerability profile consistent with the expected actions of FcRn inhibiting agents. The rapid reduction in IgG levels did not appear to be associated with any immediate safety concerns, but long-term data are still awaited. 

For TGP, clinical studies have demonstrated that when used as an adjunct with immunosuppressants, it is associated with relatively few adverse events, and the overall safety profile appears favorable. This contrasts with some of the more aggressive systemic therapies that are known to carry risks of immunosuppression and other serious side effects, thereby highlighting the potential benefit of employing a natural-product-based approach.

Overall, compared to older systemic immunosuppressants—which can have significant side effects including increased risk of infections, liver toxicity, and other systemic adverse events—these new drug candidates demonstrate promising efficacy with a more manageable safety profile.

Future Directions and Research

Ongoing Research and Development 
The landscape for Sjögren's Syndrome treatment is rapidly evolving with numerous ongoing clinical trials aimed at further validating the efficacy and safety of these new agents. Dazodalibep is moving from Phase 2 into larger Phase 3 studies that are expected to provide more definitive evidence regarding its long-term benefit and disease-modifying capacity. Similarly, nipocalimab is undergoing continued evaluation, with trial designs now being optimized to assess not only its biochemical efficacy (e.g., reduction of IgG and autoantibody levels) but also its clinical outcomes in larger patient populations. 

In parallel, researchers are exploring various combination therapies that may include anti-CD40L agents like dazodalibep alongside other immunomodulatory therapies (such as anti-BAFF biologics or additional B cell targeting agents) to achieve synergistic effects. Such combination strategies have the potential to better address the heterogeneity of Sjögren's Syndrome and its multifactorial pathogenesis. 

There is also a growing body of research investigating the underlying genetic and molecular pathways involved in Sjögren's Syndrome, with the aim of identifying additional targets for drug development. Advanced techniques in genomics and proteomics are expected to further elucidate disease mechanisms, potentially leading to the discovery of novel biomarkers that can predict treatment response and guide personalized therapy. 

Potential Future Therapies 
Looking ahead, several promising future therapies for Sjögren's Syndrome are under investigation. The current focus on biologics such as dazodalibep and nipocalimab may pave the way for additional drugs that target specific co-stimulatory pathways and cytokine networks responsible for glandular dysfunction. For instance, targeting the BAFF pathway and other B-cell survival signals represents a rational next step, as these pathways have been implicated in sustaining autoantibody production and chronic inflammation. 

In addition to these targeted immunotherapies, there is interest in exploring gene-based interventions and the use of localized gene therapy to modulate cytokine expression directly within the salivary and lacrimal glands. Such strategies could yield highly specific treatments with minimal systemic side effects. 

Furthermore, the integration of natural compounds such as TGP into mainstream treatment regimens could become a valuable adjunct approach, particularly in regions where traditional medicine is widely accepted. Future research will likely aim to refine the composition, dosing, and delivery methods for TGP to enhance its efficacy and reproducibility in clinical settings. 

Finally, the advent of personalized medicine is expected to play a crucial role in the future management of Sjögren's Syndrome. With improved biomarker identification and stratification tools, clinicians may soon be able to tailor therapeutic regimens to individual patient profiles, thereby optimizing outcomes and minimizing adverse effects. Such a paradigm shift would represent a significant advance over the current one-size-fits-all approach and may ultimately lead to the development of a disease-modifying treatment algorithm for Sjögren's Syndrome.

Conclusion 
In summary, the quest for new drugs for Sjögren's Syndrome has led to the emergence of several promising candidates that target the root causes of the disease rather than merely treating its symptoms. Recent developments include innovative biologic agents such as dazodalibep—a CD40 ligand antagonist that has demonstrated significant improvements in disease activity scores in Phase 2 trials—and nipocalimab, which functions as an FcRn antagonist to lower autoantibody levels and shows early promise in clinical studies. Additionally, total glucosides of paeony (TGP) represent a novel approach derived from traditional medicine, providing immunomodulatory effects with a favorable safety profile when used in admixture with conventional immunosuppressants.

Mechanistically, these novel agents are designed to interfere directly with key immunopathologic processes—disrupting critical T cell–B cell interactions in the case of dazodalibep or accelerating the clearance of pathogenic antibodies with nipocalimab. This level of targeted intervention distinguishes them from existing symptomatic treatments, offering hope for a true disease-modifying therapy that can halt or substantially slow the progression of Sjögren's Syndrome.

Early clinical trial results are encouraging, with significant improvements in objective and subjective measures of disease activity, although further studies are warranted to confirm long-term efficacy and safety. Meanwhile, ongoing research efforts continue to explore additional targets, combination therapies, and personalized approaches that could eventually lead to more comprehensive and effective treatment strategies for this debilitating condition.

Looking forward, it is clear that the future of Sjögren's Syndrome treatment lies not only in the refinement and expansion of these promising new agents but also in the integration of novel diagnostic markers and personalized treatment regimens. These advances are poised to transform the management of Sjögren's Syndrome from a primarily symptomatic approach to one that is truly disease-modifying, improving both quality of life and long-term outcomes for patients worldwide.

In conclusion, while no new drug has yet received regulatory approval solely for Sjögren's Syndrome, the pipeline of investigational agents—most notably dazodalibep, nipocalimab, and TGP—represents a significant breakthrough in potential disease modification. The robust efficacy signals observed in clinical trials, along with acceptable safety profiles, position these new drugs as the forefront of Sjögren's Syndrome research. As more data become available from ongoing and future studies, it is anticipated that these agents will revolutionize the treatment landscape of Sjögren's Syndrome, ushering in an era of targeted, personalized, and highly effective therapies.

Discover Eureka LS: AI Agents Built for Biopharma Efficiency

Stop wasting time on biopharma busywork. Meet Eureka LS - your AI agent squad for drug discovery.

▶ See how 50+ research teams saved 300+ hours/month

From reducing screening time to simplifying Markush drafting, our AI Agents are ready to deliver immediate value. Explore Eureka LS today and unlock powerful capabilities that help you innovate with confidence.